NeXstar, Boehringer Mannheim Therapeutics deal

Boehringer Mannheim received an exclusive right to develop and market anti-HIV nucleoside-lipid conjugates based on NXTR's lipid conjugate technology. NXTR will receive undisclosed milestones and royalties.

Boehringer has one of its own anti-HIV nucleoside-lipid conjugates in Phase I studies. NXTR will receive milestones and royalties on any such compounds developed by Boehringer. ...